GlassScriptPhysician profile
Tae In Yu
NPI 1861440141
$3,346.29
in general payments reported to CMS, 2019-2025
31 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $523 · 2021: $428 · 2022: $587 · 2023: $552 · 2024: $610 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $408.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $318.04 | 2019-2025 | Verquvo, Januvia, Belsomra |
| Abbvie INC. | $309.80 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $295.07 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $288.63 | 2019-2025 | |
| Amgen INC. | $284.73 | 2019-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $233.52 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $229.15 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $158.20 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.77 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $96.81 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.79 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $58.80 | 2020-2022 | |
| Exact Sciences Corporation | $55.46 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.20 | 2019-2023 | Trulance, Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $50.20 | 2020-2021 | |
| Smith+Nephew, INC. | $49.18 | 2022 | |
| Biogen, INC. | $43.07 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.51 | 2019-2020 | |
| Dexcom, INC. | $31.45 | 2024-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $23.69 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.66 | 2025 | Jornay Pm |
| Biohaven Pharmaceuticals, INC. | $16.85 | 2021 | |
| Astellas Pharma US INC | $15.80 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $15.32 | 2019 | |
| Corium, LLC | $14.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.87 | 2022 | |
| Portola Pharmaceuticals, LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tae Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.